The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; Astellas Pharma; Bayer; Celgene; GlaxoSmithKline; Janssen; Novartis; Pfizer; Sanofi
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Celgene; GlaxoSmithKline; Janssen; Novartis; Pfizer; Sanofi
Research Funding - Amgen; Astellas Pharma; Bayer; Celgene; GlaxoSmithKline; Janssen; Novartis; Pfizer; Sanofi
Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304).
 
Ian D. Davis
No Relationships to Disclose
 
Martin R. Stockler
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bionomics (Inst); Celgene (Inst); Medivation (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma
 
Andrew James Martin
No Relationships to Disclose
 
Vittorio Marchesin
No Relationships to Disclose
 
Olwyn Deignan
No Relationships to Disclose
 
Ray McDermott
No Relationships to Disclose
 
Wendy R. Parulekar
No Relationships to Disclose
 
Scott A. North
Honoraria - Astellas Pharma; Janssen-Ortho; Novartis; Pfizer
 
Barbara Graham
No Relationships to Disclose
 
Anne Poh Long
No Relationships to Disclose
 
Felicia T Roncolato
No Relationships to Disclose
 
Sonia Yip
Honoraria - Lilly
 
Wendy Hague
No Relationships to Disclose
 
Carlo Dazo
No Relationships to Disclose
 
Xanthi Coskinas
No Relationships to Disclose
 
Christopher Sweeney
Stock and Other Ownership Interests - BIND Biosciences; Leuchemix
Consulting or Advisory Role - Astellas Pharma; Bayer; BIND Biosciences; Genentech/Roche; Janssen Biotech; Sanofi
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Janssen Biotech (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination